Demand for discovery services recovering, says Domainex

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmaceutical industry, Pharmacology

Demand for discovery services recovering, says Domainex
Demand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.

Outsourcing-Pharma spoke with CEO Eddy Littler who explained that while much of 2009 was a tough year for many contract research organisations (CRO) in the discovery services sector, demand began recovering towards the end of the year and has continued improving into 2010.

He suggested that while initially pharmaceutical industry mergers and acquisitions, downsizing and pressure to cut costs reduced the number of discovery projects, the loss of in-house discovery capacity coupled with the need to replenish dwindling product pipelines is increasing demand for outsourced discovery.

Littler also predicted that while services like candidate screening, medicinal chemistry and DMPK will continue to be required by the pharmaceutical industry, increasingly such companies will choose to outsource entire projects to contractors with specialist technology and expertise.

Related news

Related product

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars